期刊文献+

表柔比星联合多西他赛新辅助化疗对乳腺癌患者癌组织Ki-67表达的影响及意义 被引量:33

Effect of neoadjuvant chemotherapy with docetaxel and epirubicin on Ki-67 expression in patients with breast cancer
下载PDF
导出
摘要 目的探讨表柔比星联合多西他赛新辅助化疗对乳腺癌患者癌组织Ki-67表达的影响及意义。方法选择行乳腺癌根治术的乳腺癌患者86例,术前均予表柔比星联合多西他赛新辅助化疗。化疗前及化疗后采用定量PCR法及Western blotting法检测癌组织(化疗前取穿刺活检组织,化疗后取手术切除组织)Ki-67 mRNA及蛋白表达。术后随访5年,采用Kaplan Meire生存曲线法统计无病生存期(DFS)、总生存期(OS),采用Cox比例风险回归模型分析DFS、OS与乳腺癌组织Ki-67表达的关系。结果化疗后乳腺癌组织Ki-67 mRNA及蛋白表达较化疗前均降低(P均<0.05)。根据化疗前后Ki-67 mRNA表达的变化量,以下调10%为临界值,86例患者中Ki-67mRNA下调≥10%者57例、下调<10%者39例,其DFS分别为36、22个月,OS分别为45、37个月,二者比较P均<0.01。乳腺癌组织Ki-67表达是乳腺癌患者DFS和OS独立影响因素(HR分别为1.807、1.768,P均<0.05)。结论表柔比星联合多西他赛新辅助化疗可下调乳腺癌患者癌组织Ki-67表达,而Ki-67表达与患者预后有关。 Objective To investigate the effect of neoadjuvant chemotherapy with epirubicin and docetaxel on Ki-67 expression in patients with breast cancer and its significance. Methods Eighty-six cases of patients with breast cancer treated with breast cancer radical surgery were selected in this study, epirubiein combined with docetaxel neoadjuvant chemotherapy were carried out before operation. Quantitative PCR and Western blotting were used to detect the expression of Ki-67 mRNA and protein before and after chemotherapy. After 5-year follow-up, we used Kaplan-meire survival curve method to analyze disease-free survival (DFS) and overall survival (OS) , used Cox proportional hazard regression model to analyze the relationship between DFS, OS and Ki-67 expression. Results The expression of Ki-67 mRNA and Ki-67 pro- tein in the breast cancer after chemotherapy were lower than that before chemotherapy ( all P 〈 0.05 ). According to Ki-67 mRNA expression changes, patients were further divided into higher change group (down-regulation of Ki-67 mRNA was more than or equal to 10% , 57 cases) and lower change group (Ki-67 mRNA reduced less than 10% , 39 cases). DFS of the two groups (higher and lower changes group respectively) was 36, 22 months and OS was 37, 45 months, and there were significant differences between the two groups ( all P 〈 0.01 ). Ki-67 was the an independent influencing factor for DFS and OS in patients with breast cancer ( HR were 1. 807, 1. 768, all P 〈 0.05 ). Conclusion Epirubiein and docetax- el neoadjuvant ehemotherapy can down-regulate the expression of Ki-67 in tumor tissues of patients with breast cancer, and the high expression of Ki-67 is related to the poor prognosis.
出处 《山东医药》 CAS 北大核心 2016年第24期63-65,共3页 Shandong Medical Journal
关键词 乳腺癌 新辅助化疗 表柔比星 多西他赛 Ki-67 breast carcinoma neoadjuvant chemotherapy epirubicin docetaxel Ki-67
  • 相关文献

参考文献13

  • 1Gathirua-Mwangi WG,Zollinger TW,Murage MJ,et al.Adult BMI change and risk of Breast Cancer:National Health and Nutrition Examination Survey(NHANES)2005-2010[J].Breast Cancer,2015,22(6):648-656.
  • 2Lei F,Kathrin SW,Li JJ,et al.Breast cancer in China[J].Lancet Oncol,2014,15(7):e279-e289.
  • 3Hahn SY,Ko EY,Han BK,et al.Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy[J].Eur J Radiol,2014,83(2):283-288.
  • 4Fowble BL,Einck JP,Kim DN,et al.Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer[J].Int J Radiat Oncol Biol Phys,2012,83(2):494-503.
  • 5Hafeez F,Neboori HJ,Harigopal M,et al.Is Ki-67 expression prognostic for local relapse in early-stage breast cancer patients treated with breast conservation therapy(BCT)[J].Int J Radiat Oncol Biol Phys,2013,87(2):344-348.
  • 6万安,周颖,曲皖君,王晓丽,赵洪萍,徐兵,孙多祥,赵卫东.子宫颈癌中vimentin和ki-67蛋白表达及其影响因素分析[J].中华疾病控制杂志,2014,18(9):805-807. 被引量:8
  • 7Kennecke H,Yerushalmi R,Woods R,et al.Metastatic behavior of breast cancer subtypes[J].J Clin Oncol,2010,28(20):3271-3277.
  • 8Inwald EC,Klinkhammer-Schalke M,Hofstdter F,et al.Ki-67 is a prognostic parameter in breast cancer patients:Results of a large population-based cohort of a cancer registry[J].Breast Cancer Res Treat,2013,139(2):539-552.
  • 9Wei DZ,Ying Z,Beihua K,et al.Snail family proteins in cervical squamous carcinoma:Expression and signicance[J].Clin Invest Med,2013,36(4):E223-E233.
  • 10Gandini S,Guerrieri-Gonzaga A,Pruneri G,et al.Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials[J].Ann Oncol,2014,25(3):618-623.

二级参考文献3

共引文献7

同被引文献275

引证文献33

二级引证文献226

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部